Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications call

Trial Details

NCT ID

NCT06997068

Phase

PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

HPV Positive Head and Neck Cancer

Interventions

Celecoxib
Erlotinib Hydrochloride
Imaging Procedure
Interview
Methotrexate
Questionnaire Administration

Locations (sample)

Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

Age ≥ 18 years
Histologically confirmed diagnosis of relapsed/metastatic head and neck cancer, including oral cavity, oropharynx \[human papillomavirus (HPV) posi…
Measurable or non-measurable disease is allowed
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →